Today, Blueprint Medicines Corp Inc’s (NASDAQ: BPMC) stock gained $9.12, accounting for a 8.75% increase. Blueprint Medicines opened at $103.95 before trading between $113.53 and $102.98 throughout Thursday’s session. The activity saw Blueprint Medicines’s market cap rise to $6,638,194,933 on 880,979 shares -above their 30-day average of 298,271.
About Blueprint Medicines Corp
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.